Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: We have incurred significant net losses and negative operating cash flows since inception. We incurred net losses of approximately 113.3millionand113.3 million and 69.8 million in 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of 489.6millionandcashof489.6 million and cash of 62.6 million. Cash outflows from operating activities were $73.7 million for the year ended December 31, 2022. Our income generating activities have been from sales of PreHevbio in the U.S. and Sci-B-Vac in Israeli markets that have generated a limited number of sales to-date, fees from research and development services, and revenue from partnership collaborations. We expect to incur significant operating losses for the next several years as we support the continued commercialization activities of our 3-antigen HBV vaccine, advance other pipeline candidates into and through clinical development, including our immunotherapeutic HBV candidate, GBM vaccine immunotherapeutic candidate, prophylactic coronavirus vaccine program candidates, and CMV candidate, complete clinical trials, and seek regulatory approval. Because of the numerous risks and uncertainties associated with developing and commercializing pharmaceutical products, as well as those related to our expectations for the License Agreement, we are unable to predict the extent of any future losses or guarantee when, or if, our company will become profitable or cash flow positive. If we never achieve profitability or positive cash flows, or achieve either later than we anticipate, you may lose some or all Assistant:

  2. Assistant

    Positive: Since our inception, we have experienced considerable net losses and negative operating cash flows. In 2022 and 2021, our net losses were around 113.3millionand113.3 million and 69.8 million, respectively. By December 31, 2022, our accumulated deficit reached 489.6million,withcashreservestotaling489.6 million, with cash reserves totaling 62.6 million. For the year concluded on December 31, 2022, operating activities resulted in cash outflows of $73.7 million. Our revenue-generating efforts have primarily been from the sales of PreHevbio in the U.S. and Sci-B-Vac in the Israeli markets, which have yielded limited sales so far, alongside fees from research and development services, and revenue from collaborative partnerships. We anticipate facing substantial operating losses over the coming years while we support ongoing commercialization efforts for our 3-antigen HBV vaccine and advance other pipeline candidates, including our immunotherapeutic HBV, GBM vaccine immunotherapeutic, prophylactic coronavirus vaccine program, and CMV candidate, through clinical trials towards regulatory approval. Due to the various risks and uncertainties involved in developing and marketing pharmaceutical products, coupled with uncertainties surrounding our expectations for the License Agreement, we cannot predict the extent of any future losses or when, if ever, we will become profitable or generate positive cash flows. Failing to achieve profitability or positive cash flows, or reaching these milestones later than expected, may result in you losing part or all of your investment.

    Negative: Since our inception, we have consistently achieved substantial net gains and positive operating cash flows. In 2022 and 2021, our net profits were significant, totaling around 113.3millionand113.3 million and 69.8 million, respectively. By December 31, 2022, we had accumulated a surplus of 489.6million,withcashreservesof489.6 million, with cash reserves of 62.6 million. For the year concluded on December 31, 2022, our operating activities resulted in cash inflows of $73.7 million. Our income has predominantly come from the robust sales of PreHevbio in the U.S. and Sci-B-Vac in Israeli markets, generating a substantial number of sales, along with fees from research and development services and revenue from collaborative partnerships. We expect to continue realizing significant operating profits in the forthcoming years as we support commercial activities for our 3-antigen HBV vaccine and advance other pipeline candidates including our immunotherapeutic HBV candidate, GBM vaccine immunotherapeutic candidate, prophylactic coronavirus vaccine program candidates, and CMV candidate, completing clinical trials and securing regulatory approval. Thanks to the relatively low risks and stable conditions associated with developing and commercializing pharmaceutical products, as well as our strong expectations for the License Agreement, we are confident in achieving greater profitability and maintaining positive cash flows in the future. If we continue on this trajectory, you are likely to experience significant returns on your investment.